Printer Friendly

Hybridon receives patent for Protein Kinase A oligonucleotide.

Hybridon, Inc. (Cambridge, MA) announced the issuance of United States Patent 6,624,293 entitled, "Modified Protein Kinase A-Specific Oligonucleotides and Methods of Their Use," claiming 2nd generation antisense oligonucleotides targeting the RI alpha regulatory subunit of Protein Kinase A. Included in the patent are product claims covering Hybridon's GEM231 2nd generation antisense drug candidate. Other issued claims in the patent cover several other modified versions of the GEM231 product and therapeutic compositions containing 2nd generation oligonucleotides.

The present patent along with the parent, United States Patent 5,969,117, give Hybridon a broad portfolio of 2nd generation antisense oligonucleotides targeting the RI alpha subunit of PKA. In addition, the present patent further expands the patent protection of Hybridon's 2nd generation antisense chemistry employed in GEM231 and covered by previously issued patents including United States Patent Nos. 5,652,355; 6,143,881; 6,346,614 and their oral delivery United States Patent Nos. 5,591,721; 6,608,035.

Presently, Hybridon is conducting a phase 1/2 trial at Vanderbilt University Medical Center of GEM231 as a combination therapy with irinotecan.

Sole inventor on the 6,624,293 patent is Dr. Sudhir Agrawal, Hybridon's President and Chief Scientific Officer. Dr. Agrawal is also a co-inventor of the other patents listed in this release.

Hybridon is a leader in the discovery and development of novel therapeutics and diagnostics, based on synthetic DNA. The Company now has four technology platforms: 1) Synthetic immunomodulatory oligonucleotide (IMOTM) motifs that act to modulate responses of the immune system; 2) Antisense technology which uses synthetic DNA to block the production of disease-causing proteins at the cellular level; 3) Synthetic DNA drug candidates that enhance the antitumor activity of certain marketed anticancer drugs, thereby increasing their effectiveness; and 4) Cyclicon probes, novel synthetic DNA structures for identifying gene function, which can be used for target validation and drug discovery as well as for PCR-based gene amplification.

Hybridon, Inc.

+1-617-679-5500

www.hybridon.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Sep 1, 2003
Words:326
Previous Article:Gene knockouts yield drug discovery programs for Lexicon.
Next Article:Affymetrix Provides Johnson & Johnson Pharm R & D Access.
Topics:


Related Articles
Hybridon announces issuance of a dominant second generation antisense patent.
Vertex receives patent for drug discovery targeting kinase gene family.
Hybridon obtains second generation ribozyme patent.
Antisense chemistry interference involves Hybridon.
Hybridon obtains patent for second generation antisense oligonucleotides.
Hybridon receives patent for orally administering second generation antisense oligonucleotides.
New patent adds to Hybridon's antisense chemistry patent portfolio.
BASF obtains United States patent.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |